Camlin Fine Sciences (CAMLINFINE) Q4 24/25 earnings summary

Executive summary

• Consolidated annual revenue for FY25 grew 15% year-over-year to INR 1,666 crore, with core business EBITDA margin at 12.5% and improved net debt position.

• Blends segment revenue rose 18% YoY to INR 878 crore, with strong growth in North America and domestic markets; Aroma Ingredients contributed INR 176 crore.

• Discontinued operations in Europe and China were fully impaired and abandoned, with cash burn expected to reduce significantly.

• Major structural changes included the acquisition of Vitafor Belgium and Vinpai SA, and a successful rights issue in January 2025.

• Audited financials for FY25 were approved with unmodified opinions; the 32nd AGM is scheduled for August 8, 2025.

Financial highlights

• Q4 FY25 turnover was INR 437 crore, up from INR 431 crore in the previous quarter; Q4 adjusted EBITDA was INR 594 million, up 20.7% YoY.

• FY25 PAT from continuing operations was INR 494 million, with a PAT margin of 3.0%.

• Consolidated net loss after tax for FY25 was INR 1,703.54 million, compared to a loss of INR 869.11 million in FY24, due to exceptional items.

• Net debt reduced to INR 4,918 million as of March 2025, with net debt-to-equity ratio improving to 0.55x.

• Rights issue of INR 2,247 million in January 2025; NCD of INR 1,000 million repaid in Q4 FY25.

Outlook and guidance

• Blend business expected to grow at 20% CAGR over the next two years, with EBITDA margins in the high teens.

• Vanillin plant capacity utilization targeted to reach 100% in two years, up from current 45%-50%.

• Gross margin expected to remain in the 45%-55% range, with potential to trend higher as vanillin ramps up.

• Board and auditors confirmed going concern basis for both standalone and consolidated financials.

• No material impact expected from liquidation of non-material subsidiaries.